REFERENCES
1. Sahin TK, Rizzo A, Aksoy S, Guven DC. Prognostic significance of the royal marsden hospital (RMH) score in patients with cancer: a systematic review and meta-analysis. Cancers. 2024;16:1835.
2. Nakamura H, Saji H, Shinmyo T, et al. Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography. Lung Cancer. 2015;87:28-33.
3. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32:3059-68.
4. Jennette JC. Overview of the 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17:603-6.
5. Ricketts CJ, De Cubas AA, Fan H, et al. Cancer Genome Atlas Research Network. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2024;43:113063.
6. Vargová D, Dargaj J, Dohál M, et al. Immune analysis of urine and plasma samples from patients with clear cell renal cell carcinoma. Oncol Lett. 2024;27:281.
7. Takahashi M, Kume H, Koyama K, et al. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT. Clin Nucl Med. 2015;40:936-40.
8. Betsunoh H, Fukuda T, Anzai N, et al. Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma. BMC Cancer. 2013;13:509.
9. Betsunoh H, Sakamoto S, Kaji Y, et al. Clinical significance of 18F-fluorodeoxyglucose and glucose transporter 1 mRNA in clear cell renal cell carcinoma. Anticancer Res. 2021;41:5179-88.
10. Kawakami Y, Ohta S, Sayem MA, Tsukamoto N, Yaguchi T. Immune-resistant mechanisms in cancer immunotherapy. Int J Clin Oncol. 2020;25:810-7.
11. Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol. 2017;24:311-35.
12. Nakajima R, Matsuo Y, Kondo T, Abe K, Sakai S. Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with renal cell carcinoma. Clin Nucl Med. 2017;42:e177-82.
13. Ito K, Yoshii H, Sato A, et al. Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol. 2011;186:430-5.
14. Lee MH, Theodoropoulos J, Huuhtanen J, et al. Immunologic characterization and T cell receptor repertoires of expanded tumor-infiltrating lymphocytes in patients with renal cell carcinoma. Cancer Res Commun. 2023;3:1260-76.
15. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-63.
16. Sobin LH, Gospodarowicz MK, Wittekind CH. UICC. In: TNM Classification of Malignant Tumors. 7th ed. New York, Wiley-Blackwell 2009; 255-257.
17. Salgado R, Denkert C, Demaria S, et al. International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259-71.
18. Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013;108:901-7.
19. Kitajima K, Higuchi T, Fujimoto Y, et al. Relationship between FDG-PET and the immune microenvironment in breast cancer. Eur J Radiol. 2023;158:110661.
20. Zganjar A, Khanna A, Joyce D, et al. Mayo clinic validation of the AUA risk groups for localized renal cell carcinoma. J Urol. 2024;212:331-41.
21. Wang MF, Cai JR, Xia H, Chu XF. Predictive efficacy of the preoperative neutrophil-lymphocyte ratio in lymph node metastasis of cN0 hormone receptor-positive breast cancer. Sci Rep. 2024;14:14216.
22. Yu J, Huang L, Dong T, Cao L. Prediction of outcomes after chemoradiotherapy for cervical cancer by neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio. J Obstet Gynaecol. 2024;44:2361858.
23. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551-5.
24. McConkey B, Davies P, Crockson RA, et al. Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis. Ann Rheum Dis. 1979;38:141-4.
25. Shi DY, Xie FZ, Zhai C, Stern JS, Liu Y, Liu SL. The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells. Mol Cancer. 2009;8:32.
26. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8:143-53.
27. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1α (HIF-α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol. 2003;23:9361-74.
28. Bacon AL, Harris AL. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med. 2004;36:530-9.
29. Chan DA, Sutphin PD, Nguyen P, et al. Targeting GLUT1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011;3:94ra70.
30. Milella M, Rutigliano M, Lasorsa F, et al. The role of MUC1 in renal cell carcinoma. Biomolecules. 2024;14:315.
31. Filippin LI, Vercelino R, Marroni NP, Xavier RM. Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol. 2008;152:415-22.
32. Duvigneau JC, Luís A, Gorman AM, et al. Crosstalk between inflammatory mediators and endoplasmic reticulum stress in liver diseases. Cytokine. 2019;124:154577.
33. Okada Y, Takahashi A, Ohmiya H, et al. Genome-wide association study for C-reactive protein levels identified pleiotropic associations in the IL6 locus. Hum Mol Genet. 2011;20:1224-31.
34. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37:11553-72.
35. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663-71.
